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Introduction
The introduction of molecular biology techniques into the 
field of endocrinology has allowed the identification of 
single gene mutations as a cause for many endocrine 
hereditary syndromes. In many cases, and this certainly is 
true for the mutations in the receptors for luteinizing 
hormone (LH) and follicle-stimulating hormone (FSH) 
described herein, the studies have ascertained at the 
molecular level the function of these mutated genes, 
functions that previously had been shown in physiological 
studies. In this review mutations in gonadotropin receptors 
will be discussed in relation to the phenotype of the 
patients in which these mutations were demonstrated,
Among the gonadotropin receptor mutations many are 
in the LH receptor gene, and only two changes were 
found in the FSH receptor molecule. For this reason the 
major part of this review deals with mutations in the LH 
receptor gene and their effect on phenotype.
A ctivating m u ta tio n si
LH recep tor Activating mutations in the LH receptor 
gene were first identified in patients with familial male- 
limited precocious puberty (FMPP; for an overview of 
phenotypes see Table 1) (Kremer et al. 1993, Shenker et al. 
1993). In boys, these mutations lead to precocious puberty 
at an early age (before the age of 4 years); in some cases an 
enlarged penis was noted even at birth (Gondos et al.
1985). This phenotype is the consequence of increased 
androgen production by testicular Ley dig cells during the 
fetal and postnatal period irrespective of the presence of 
LH or human chorionic gonadotropin (hCG). The Ley dig 
cells are stimulated continuously through the expression of 
the mutated LH receptor allele not affected by the 
expression of the other, wild type, allele.
Most amino acid changes that have been identified in 
the constitutively active LH receptor are located in the 6th 
transmembrane segment and in the C-terminal part of the 
flanking 3rd intracellular loop (Table 2). These findings 
are in agreement with the current model of the mechan­
ism of signal transduction of the glycoprotein hormone
receptors. The 3rd intracellular loop and its flanking 
6th transmembrane segment are intimately involved in 
coupling to Gs, the G protein that activates adenylyl 
cyclase. However, similar to the thyroid-stimulating hor­
mone (TSH) receptor (Tonacchera et al 1996), mutations 
in parts of the LH receptor outside the 6th transmembrane 
segment and the 3rd intracellular loop, such as M 398T 
in the 2nd (Kraaij et al. 1995), and I^42L in the 5th 
transmembrane segment (H Kremer, H  G Brunner, 
A P N  Themmen & J W  M Martens, unpublished obser­
vations, Laue et al, 1995#) are also found. Activating amino 
acid changes may even be identified in die region of the 
receptor that connects the leucine-rich repeat segment of 
the large extracellular binding domain to the transmem­
brane domain (Bhowmick ct al, 1996), as has been shown 
in the TSH receptor (G Vassart, personal communication).
W hat is the consequence of these LH receptor gene 
mutations for the carrier male or female? The hereditary 
pattern is autosomal dominant, but only males have 
precocious puberty. The dominance of the mutation is 
explained by the gain of function character of the mutants, 
but the limitation of the syndrome to male subjects is less 
easily understood (see below). Male sex differentiation 
depends on the presence of S R Y , the testis determining 
region of the Y chromosome, that directs differentiation of 
the indifferent gonads into testes. Subsequently, androgen 
production by the testis induces male differentiation of the 
Wolffian ducts, urogenital sinus and growth and differen­
tiation of the external sex organs. During the fetal period 
of testis differentiation, Ley dig cell activity is dependent on 
the presence of maternal hCG, and the cells express the 
LH receptor gene. Although Ley dig cells continue to 
express the LH receptor after birth, they are not activated 
because LH is present at very low levels until puberty. 
Puberty is induced when the hypothalamic-pituitary-testis 
axis is established, LH is secreted and the testicular Ley dig 
cells start to produce androgens again. In contrast, an LH 
receptor gene that carries an activating mutation will not 
only stimulate Leydig cells during sex differentiation, but 
also continue to do so after birth, resulting in very early 
precocious puberty. The severity of the LH receptor
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Table 1 Overview of phenotypes
Phenotype
Defect 9-
Receptor
LH
FSH
Activated
inactivated (partial or complete)
Activated
Inactivated
Familial male-limited precocious puberty 
Pseudohermaphroditism (partial or complete) 
Rescue from hypophysectomy (see text) 
Impaired spermatogenesis
None
Primary amenorrhea
?
FSH insensitivity syndrome
?, No phenotype described.
Table 2 Overview of gonadotropin receptor mutations
In vitro
Receptor
LH
FSH
Phenotype Amino acid change1 activity Location References
c 133r ? EC Misrahi et al, 1996
S m 398t + TM2 Kraaij et al. 1995, Laue et al. 1995a, Yano et a/. 1996
i542l H“ TM5 Laue et a/. 1995a
a c 545* — TM5 Laue et al. 1995c
cÎ/S
1^554+ ?» IL3 Latronico et al. 1996
ê d 5G4g + IL3 Laue et al. 1995a
a560v + IL3 Latronico et al. 1995
<3 M571l + TM6 Kremer et al. 1993, Kraaij et al. 1995
S A572V + TM6 Yano et al. 1995
i575l + TM6 H Kremer, HG Brunner, APN Themmen & 
JWM Martens unpublished, Laue et a/. 1995b
J 5 7 7 , + TM6 Kosugi et al. 1995
c? D57ßG + TM6 Kremer et al. 1993, Shenker et al. 1993
a 0 5 7 Q y + TM6 Laue et al. 1995a
a CSB1R TM6 Laue et al. 1995a
¿ /9 ^593 p — TM6 Kremer et al. 1995, Toledo et al. 1996
a S616y — TM7 Latronico et al. 1996
<3 d 567g + TM6 Gromoll et al. 1996
9 A1üyV EC Aittomaki et al, 1995
flWild type amino acid, followed by the position according to the numbering of Minegishr et a/. (1990) and the mutant amino acid; \  nonsense mutation of 
that codon to a stop; ?, in vitro activity not tested; +, constitutively active; - ,  partially or completely inactivated.
mutation determines the age at which pubertal develop­
ment becomes obvious. Lane et al (1995rt) reported that 
the LH receptor with the D 578Y mutation showed a
_C *7 Li
higher activity in the absence of hCG than the D G 
mutant. They correlated this difference to the clinical 
phenotype of the earner of the D 578Y mutation, a boy 
who already showed signs of puberty at the age of one year 
(Babovic-Vuksanovic et aL 1994). W e have made similar 
observations (H Kremer, H G Brunner, A P N  Themmen 
& J W M  Martens, unpublished observations).
Although the constitutively active LH receptors show 
elevated basal activity, this activity will still increase upon 
stimulation with endogenous LH when true puberty com­
mences . We have mimicked the heterozygous situation in 
FMPP patients by transfecting constitutively active LH 
receptor mutants into mouse MA10 tumour Leydig cells 
that express the endogenous mouse LH receptor gene 
(Themmen & Brunner 1996). These experiments showed
that the increased basal cAMP levels caused increased 
steroid hormone production by Leydig cells. In addition, 
the cells were still responsive to higher concentrations of 
LH or hCG. The mutation causes only moderate activation 
of the receptor and modulation of receptor activity by 
endogenous LH is still possible. Thus, the gonadotropin- 
releasing hormone (GnRH)-LH-testosterone negative 
feedback is still intact in these males, and clinical signs of 
continuous maximal androgen production are not found.
Female sex differentiation during fetal life does not 
depend on LH or hCG, and LH receptors are not 
expressed. Also the onset of puberty is more dependent on 
FSH rather than on LH, since LH receptor expression in 
the ovarian granulosa cells only occurs in the presence of 
FSH. Therefore, activating mutations in the LH receptor 
gene do not affect female development.
Adult females carrying a constitutively active LH recep­
tor gene do not present with a clear phenotype. This
journal of Endocrinology (1997) 153, 179-183
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finding is unexpected and not completely understood. The 
timing of ovulation which is regulated by LH does not 
appear to be affected, since no fertility problems in female 
carriers of an activating LH receptor mutation have been 
reported. Possibly at the time of ovulation, the follicular 
LH receptors have to be maximally stimulated by LH 
to induce ovulation. Although constitutively active LH 
receptors cause a high basal cAMP production when ex­
pressed in vitro, addition of large amounts of hCG or LH still 
leads to further enhancement of cAMP production for a 
normal ovulatory LH peak. Recently, a clinical study of 
a female carrier of the D578G mutation was published 
(Rosenthal et al. 1996). The hormonal responses to a G nR H  
agonist challenge were found to be normal, and the authors 
suggested that the mutation did not activate LH receptor 
function beyond the pubertal level, and that the negative 
feedback systems that regulate ovarian function are intact.
FSH recep tor To date only one patient carrying an 
activating FSH receptor mutation has been reported 
(Gromoll et al. 1996). This male patient was identified 
in an unexpected way. After diagnosis of a pituitary 
adenoma, the patient was hypophysectomized and substi­
tuted with glucocorticoids, T4 and androgens. Surpris­
ingly, the patient proved to be fertile notwithstanding the 
complete absence of pituitary FSH. Because it is thought 
that both FSH and androgens are necessary for correct and 
complete spermatogenesis in the human, Gromoll et al. 
(1996) hypothesized that a constitutively active FSH 
receptor might be the cause of the intact spermatogenesis 
in this hypophysectomized, androgen-treated man. Indeed 
an FSH receptor gene alteration was found, and expression 
of this mutant receptor in COS cells resulted in the 
production of approximately 2*5-fold more cAMP than in 
control cells transfected with the wild type FSH receptor. 
The increases in cAMP may be slight, but their effects on 
Sertoli cell function may be strong (Fritz et a l 1978). The 
unexpected fertility in this hypophysectomized man 
strongly suggests that the identified amino acid change is 
the cause of the active spermatogenesis. In the absence of 
information about other cases and details such as testis 
histology or abnormalities during puberty, it remains 
unclear whether an FSH receptor imitation with such a 
mild in vitro effect will alter sex differentiation or male 
fertility under normal conditions.
No female cases carrying a constitutively active FSH 
receptor molecule have been reported. It is difficult to 
envisage what the phenotype of such a case would be. One 
could argue that the higher FSH receptor activity might 
force more follicles to grow leading to an increase in 
pre-ovulatory follicles and a higher incidence of dizygotic 
twinning. Correlations between FSH levels or action and 
dizygotic twinning have been indicated (Martin et aL 
1984, 1991), but in a recent study no linkage disequilib­
rium with respect to genes for FSH(3, CGp, inhibinPB and 
GnRH could be found in mothers of dizygotic twins
(Chenevix-Trench et al 1993). It would seem logical to 
extend these studies to include the FSH receptor. H ow - 
ever, to date no FSH receptor studies in women with 
multiple dizygotic twinning have been reported. An 
attenuating effect on fertility might occur when a mutation 
in the FSH receptor causing hypersensitivity to FSH has 
occurred. Such a receptor might stimulate the growth of 
small follicles, and lead to follicle maturation before the LH 
peak occurs. Finally, subtle effects of aberrantly activated 
FSH receptors might adversely affect follicle selection or 
timing of ovulation. A m inim um  concentration of serum 
FSH, the so-called FSH threshold, appears to be essential 
for follicle selection (Fauser et ah 1993, van Santbrink et al. 
1995). A mutant FSH receptor that does not respond 
to slight changes in FSH might influence this delicate 
regulation, and affect female fertility.
Inactivating mutations
LH receptor The first described cases with inactivating 
LH receptor mutations were 46,XY male pseudo - 
hermaphrodites that suffered from a severe form of Leydig 
cell hypoplasia (type 1 (Toledo et al 1985)) characterized 
by a female external phenotype, a small blind-ending 
vagina, inguinal testes and absent glandular breast tissue. A 
homozygous DNA mutation leading to a A593P amino 
acid change was identified in these cases (Kremer et al 
1995). Upon expression in vitro the mutant LH receptor 
was found to be completely unable to transduce the 
L H /hC G  signal to the Gs protein and adenylyl cyclase, 
although L H /hC G  binding was relatively normal (Kremer 
et al 1995), suggesting that the homozygous LH receptor 
gene mutation caused the Leydig cell hypoplasia pheno­
type. In another pedigree a homozygous nonsense m u­
tation was found that results in truncation of the LH 
receptor (Latronico et al 1996). Although this mutation 
was not functionally evaluated, one may expect that the 
truncation in the 3rd intracellular loop (R 545Stop) com­
pletely abolishes signal transduction, because the domains 
that confer G protein coupling are not present. Until now 
affected patients are found in inbred families, and are 
homozygous for the LH mutations. Only one compound 
heterozygote has been described (see below). In these 
males the phenotype, complete pseudohermaphroditism, is 
consistent witli complete absence of testosterone-mediated 
genital development. This underscores the crucial role of 
the liC G /L H  receptor in male sex differentiation.
A second variant of Leydig cell hypoplasia (LCH type 2) 
was described by Toledo (1992). This milder LCH type
2 phenotype is characterized by undervirilization and a 
micropenis and is expected to be the result of a low but not 
absent androgen production during sex differentiation, 
caused by LH receptor mutations that compromize, but do 
not completely inhibit hC G  binding and signal transduc­
tion. Recently, a homozygous S616Y amino acid change in 
the 7 th trails membrane segment of the LH receptor was 
identified in a patient with no other clinical manifestations
Journal of Endocrinology (1997) 153/ 179-183
182 a  p N t h e m m e n  and others • Gonadotropin receptor mutations
of subvirilization but a micropenis (Latronico et al. 1996). 
The same S6l6Y amino acid change was found in a 
compound heterozygous Leydig cell hypoplasia patient 
(Laue et al. 1996). The other allele in this patient encoded 
a completely inactive LH receptor with missing exon 8 
(no ligand binding). Unexpectedly, in the former report 
(Latronico et at. 1996), the S616Y mutant receptor when 
tested in vitro showed complete inability to bind LH or 
stimulate cAMP production, possibly caused, by trapping of 
the protein within the intracellular organelles, while Laue 
et al (1996) observed residual activity better fitting the 
mild phenotype. A mutation in the leucine-rich repeat 
segment of the LH receptor (C133R) in an LCH type 2 
patient has been described that may interfere with high
affinity LH /hCG  binding (Misrahi et al. 1996).
Recently, the female counterpart of LCH type 1 has been 
reported (Toledo et al 1996). In this 46,XX woman a 
homozygous inactivating LH receptor mutation was found, 
but she presented with a relatively mild phenotype: primary 
amenorrhea with normally developed primary and secondary 
sex characteristics. The patient is a sister of the two 46,XY 
pseudohermaphrodites described by Kremer et al. (1995), 
and carries the same homozygous mutation in the LH 
receptor gene rendering the LH receptor protein completely 
inactive. An hCG challenge revealed complete resistance to 
hCG/LH. Clinical examination revealed a small uterus, 
normal-sized vagina with thin walls and hyposecretory func­
tion and some signs of decreased bone mass. All these 
observations are indicative of low estrogen levels. As was 
expected, serum estrogen levels were found to be always in 
the low-normal range for the follicular part of the menstrual 
cycle. No pre-ovulatory follicles or corpora lutea were ob­
served in the ovary. Some collapsed antral follicles with theca 
cells that had a luteinized appearance, as well as clusters of 
primordial follicles were noted. These observations are all 
consistent with absence of LH receptor function leading to 
amenorrhea, and very low estrogen production. In another 
pedigree a similar female patient was described with an 
inactivating mutation in the LH receptor gene that leads to a 
truncation of the LH receptor protein (Latronico et al 1996).
These first results of the investigation of mutations in 
the LH receptor gene indicate that the phenotypic effect of 
a mutation that completely inactivates the LH receptor is 
much more severe in males than in females. This differ­
ence between sexes is caused by the dependence of male 
sex differentiation on fetal testosterone production by fetal 
Leydig cells under the control of maternal hCG.
FSH receptor In females, inactivating FSH receptor gene 
mutations appear to have a much more severe effect on 
phenotype than the inactivation of the LH receptor mol­
ecule. Patients carrying an inactivating mutation in the FSH 
receptor gene have unresponsive ovarian cells, almost absent 
female sex steroid production resulting in under­
developed secondary sex characteristics (Aittomaki 1994, 
Aittomaki et at. 1995). In our view, the nomenclature of this
journal of Endocrinology (T997) 153, 179-183
syndrome needs clarification. Ovarian dysgenesis has been 
used, but this term suggests that the ovary has never formed 
as the result of a defect during fetal development. However 
in these patients the dysfunctioning ovary is the result of 
unresponsiveness to FSH. In analogy to the use of androgen 
insensitivity syndrome for the now defunct term testicular 
feminization, we propose to use the term FSH insensitivity 
syndrome instead of ovarian dysgenesis for these patients.
The observations in the patients with an FSH receptor 
mutation (Aittomaki et al. 1995) fit the model of endocrine 
regulation of ovarian function: FSH stimulates growth of 
the follicles, and subsequent induction of LH receptors. 
Consequently, the lack of an FSH signal results in the 
complete absence of growing follicles and concomitantly 
an absence of estrogens. In contrast, absence of signaling 
through the LH receptor allows for follicular growth and, 
albeit limited, estrogens being produced.
A controversial situation exists in the male. Homo- 
zygous carriers of the same FSH receptor mutation as the 
female patients appear to have small testes indicating 
absent or poor spermatogenesis (I Huhtaniemi, personal 
communication, Aittomaki et, al 1995). In light of the 
eifect of the activating FSH receptor gene mutation in the 
fertile hypophysectomized man described above, this is a 
puzzling finding. O n the one hand a minimally active 
FSH receptor rescues fertility in the absence of endogen­
ous FSH, while on the other hand a compromized and 
minimally active FSH receptor causes infertility in the 
presence of high levels of FSH (both findings in the 
presence of androgens, either administered or endogen­
ous). Furthermore, the FMPP patients that go into 
puberty because of their constitutively active LH receptor, 
do show onset of spermatogenesis in the absence of FSH. 
The results of investigation of the males carrying an 
inactive FSH receptor gene are eagerly awaited, and 
certainly more male patients need to be screened before 
more definite conclusions can be drawn.
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